Researchers pin Longevity hopes on new CRISPR gene editor

$34M in new Trucode funding could challenge CRISPR gene editing domination of genetic engineering market.

Have we reached the thin end of the CRISP? For scientists looking to permanently alter the genomes of humans and animals, CRISPR has, for a while now, been the quick and cheap method of choice. But now, a new technology is set to give the “miracle method [1]” a run for its money in the gene editing market. And what’s more, biotech startup Trucode Gene Repair is hoping that its new gene editing technique will not carry the risk of unintended changes to the genome that other methods have.

The San Francisco-based biotech announced last Tuesday that it has raised $34M in financing with deep-pocketed investors that include Kleiner Perkins and GV (formerly Google Ventures). The Trucode method is based around delivering the new gene via a nanoparticle that is intravenously injected, rather than delivered via an engineered virus like CRISPR. These nanoparticles contain a DNA correction sequence as well as strands of synthetic genetic material called peptide nucleic acids (PNA).

Longevity.Technology: CRISPR gene editing has made headlines for all the right – and the wrong – reasons. Despite the hyperbole, concerns have been raised about CRISPR’s fiddling with the genome potentially causing cancer through mutations [2] and some patients having a pre-existing immunity to it [3]. Competition is often the catalyst for invention and improvement, but we advise our readers to take a cool-headed approach to the genetic engineering market. Right now the only viable applications of this technology are for those suffering from severe congenital diseases, where one or two identifiable parts of the genome are in need of repair. For those looking for a gene editing technique to expand their lifespan – expect to be disappointed, the medical and ethical challenges are far away from being solved.

The TRL score for this Longevity.Technology domain is currently set at: ‘Principles are demonstrated through experimentation.’

TRL 2

The TRL score for the technology addressed in this article is: “Early proof of concept demonstrated in the laboratory.”

Peter Glazer of Yale University told the National Institutes of Health last year: “One of the big advantages of PNA and donor DNA is that the off-target rate is much lower than CRISPR, the most well-known gene-editing tool. The other advantage is that they can be administered in vivo, by simple intravenous injection of the nanoparticles. You don’t have to take the cells out of the body, because the nanoparticles provide a very effective and safe delivery method [4].”

Once injected, the nanoparticles travel through the patient’s body until they reach their intended target organ. It is here that they are taken up by the organ’s cells – delivering the corrective-DNA and PNA payloads. Once inside the cells, the PNA binds with the original DNA helices to form three strands. Since DNA is a double helix, composed of two strands, the “triplex” DNA structure triggers a natural DNA repair mechanism in the cell. When the DNA is repaired by this mechanism, it inserts the DNA correction sequence that was delivered by the nanoparticle.

Trucode says that the technology’s initial focus will be on developing therapies for sickle cell disease and cystic fibrosis, but that it plans to tackle many inherited diseases in the future [5].

Trucode’s gene editing method is based on research by Yale University professors Peter Glazer, Mark Saltzman and Marie Egan. They published the results of a preclinical study last year that showed the PNA and nanoparticle technology had successfully resulted in gene edits in mice suffering from the blood diseases beta thalassemia and cystic fibrosis. In addition, the number of off-target mutations from triplex gene editing was “substantially lower” than that reported for other gene editing technologies such as CRISPR, zinc-finger nucleases and Talens [6].

Dr Marshall Fordyce, Founder and Chief Executive Officer of Trucode, said: “The medical promise of gene editing to cure patients with genetic disease has arrived but has not realized its full transformative potential. Our technology could address key challenges faced by the industry, including editing fidelity, immune reactions, delivery, scaled manufacturing, and intellectual property [7].”

[1] https://bit.ly/2jVrNUB
[2] https://www.nature.com/articles/s41591-018-0150-3
[3] https://bit.ly/2BKRizM
[4] https://bit.ly/2m1loJO
[5] https://bwnews.pr/2lTHP3H
[6] https://www.trucodegene.com/news-2019sep10
[7] https://bit.ly/2kTlCT4
Image: Alexander Lukatskiy / Shutterstock.com
Eleanor Garth
Staff Writer and Community Manager Following a degree in Classics, Eleanor organised biomedical engineering conferences and provided research support at Imperial College London and various London hospitals, before working as a science and medicine journalist.

Latest articles

eGenesis’ xenotransplantation trials move closer to in-human

eGenesis' groundbreaking xenotransplantation work with Massachusetts General Hospital to be expanded through additional collaboration. eGenesis has announced it is expanding its research collaboration with the...

New Japanese stem cell clinical trial for aging frailty

Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...

Unlocking the Longevity potential of our oceans

Biologist focuses on the coast of Oman to discover how extreme environments and oceanic life could provide sources for Longevity. With issues like climate change, overfishing...

Alkahest announces phase 2 study treatment of cognitive impairment

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients. Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...